This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $45.74, moving -0.54% from the previous trading session.
Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.88, marking a +0.81% move from the previous day.
Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.04, moving -0.41% from the previous trading session.
Should You Invest in Amphastar (AMPH) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Amphastar (AMPH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.30, moving -0.73% from the previous trading session.
Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why
by Zacks Equity Research
Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
by Zacks Equity Research
Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.
HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.
Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical
by Zacks Equity Research
Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.
Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients
by Zacks Equity Research
Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
by Zacks Equity Research
TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.
Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $61.38, moving -0.44% from the previous trading session.
Amphastar Pharmaceuticals (AMPH) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.
Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed at $63.25 in the latest trading session, marking a +1.48% move from the prior day.
The Zacks Analyst Blog Highlights Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations
by Zacks Equity Research
Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations are included in this Analyst Blog.
5 Must-Buy High-Flying Mid-Caps to Enhance Your Portfolio
by Nalak Das
We have narrowed our search to five mid-cap stocks with more than 50% returns year to date. These are: PGTI, SHAK, IDCC, ANF, AMPH.